Revalia Bio's Quest to Replace Animal Models with Human Organs
Inside Precision Medicine profiles Pamir Ventures portfolio company Revalia Bio, whose platform uses donated human organs unsuitable for transplant to test drugs — aiming to replace animal models in preclinical research.
Using normothermic machine perfusion, Revalia keeps donated organs functioning outside the body for roughly five days — long enough to dose, monitor, and sample them the way a trial would. The result is human-relevant evidence at the earliest stage of development.
The stakes are well documented: up to 90% of drug candidates that pass animal testing still fail in human trials. Revalia's answer is to front-load real human biology, so developers learn what the clinic would teach them — years earlier and at a fraction of the cost.